parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in somatotrophs	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 6329

PHF21B in dopamine neurons, braak-0.68 (p 0.045) → +0.14 (p 0.722)receipt 6338
PHF21B in astrocytes, braak-0.26 (p 0.493) → -0.22 (p 0.570)receipt 6337

receipt 6338: PHF21B in dopamine neurons, braak

power: full sample -0.35 (p 0.153, n 18), 95% CI -0.70 to +0.14. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.32 (p 0.198, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.050, n 18). not the mix.
skeptic: leave-one-out range -0.47 to -0.27, sign flips 0; without severely affected donors -0.35 (p 0.153, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PHF21B in dopamine neurons.

case closed: nothing better to follow up.

receipt 6337: PHF21B in astrocytes, braak

power: full sample -0.15 (p 0.544, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.16 (p 0.521, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.12 (p 0.646, n 18). could be the mix.
skeptic: leave-one-out range -0.32 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.544, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PHF21B in astrocytes.

case closed: nothing better to follow up.

loading the receipts